香港股市 將收市,收市時間:4 小時 13 分鐘

Merck & Co., Inc. (MRK)

NYSE - NYSE 延遲價格。貨幣為 USD。
加入追蹤清單
94.41+1.28 (+1.37%)
收市價: 04:05PM EDT
94.71 +0.30 (+0.32%)
收市後: 07:59PM EDT
登入即可發佈回覆。

Yahoo有權移除任何不符 規範服務條款(包括粗俗或鼓勵犯法)之留言。

  • m
    marco
    $VBIV conversation
    Could $MRK buyout $VBIV in 2022?
    VBI Vaccines is set to become a leader in the areas of Hep-B + GBM. Their COVID pipeline coming up for VBI-2905 data will validate further NRC & CEPI funding.

    This plausible speculation has a lot of extensive DD done to come to the conclusion that Merck will either buyout $VBIV or do a major partnership for theor Hep-B & oncology pipeline.

    CEO remarks last Call:

    "But we're really excited about the TRIPLE COMBINATION when it reads out in the second half of this year through our colleagues at Brii and what informs for the rest of the world. We VBI has retained Ex-China rights to this. Once we have some data, if it is successful, touch-wood, then WE WILL HAVE SOME INTERESTING DISCUSSIONS WITH SOME OTHER PLAYERS WHO LOOK TO MAKE SIGNIFICANT MOVES IN THIS FIELD FOR THE REST OF WORLD RIGHTS."

    https://www.reddit.com/r/VBIV/comments/tp2wi3/merck_potential_buyout_candidate_for_vbiv_dd_by/
  • C
    Cured
    $SLS conversation
    $bmy $mrk b like
    Median Overall Survival of 45.7 Weeks for Patients Treated With Combination Therapy for at Least One Month; Median Overall Survival in Relapsed/Refractory Patients Treated with Standard of Care is 28 Weeks
  • P
    P509$
    $SLS conversation
    Kind of deal I expect we'll see here $BMY is competing with $MRK - Gps gives both companies an effective therapy for Ovarian cancer.
    https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-buy-turning-point-41-bln-2022-06-03/
  • C
    Cured
    $SLS conversation
    A reminder, $mrk Has no other trials for these Platinum Refractor patients, Keytruda ineffective alone, and not one other Merck Partnership is in trial - Gps +Keytruda has a 54% Disease Control rate and a median Os yet to be reached, but already longer than all other therapies.
    All enrolled patients were resistant to standard of care platinum-based therapy and 78.5 percent of evaluable patients were refractory to or had failed their first- or second-line therapies with 21.5 percent having failed three or more lines of therapy, including one patient who failed five previous lines of therapy. Of the 15 patients, 13 received at least three doses of GPS, the last of which was in combination with pembrolizumab, and were evaluable for response outcomes.

    Summary of Top-Line Clinical Data
    An ad hoc analysis of clinical outcomes in this cohort shows a disease control rate (DCR), the sum of overall response rate and rate of stable disease, of 53.9 percent at a median follow-up of 43.1 weeks. In a checkpoint inhibitor single agent study in a similar platinum-resistant ovarian cancer patient population treated with a checkpoint inhibitor alone, the observed DCR was 37.2 percent, consistent with a DCR rate increase of 45 percent in the GPS combination with pembrolizumab over that seen for checkpoint inhibitors alone.
    Median progression-free survival (PFS) was 12 weeks compared to 8.4 weeks for checkpoint inhibitors alone seen in studies with similar patient populations, a 43 percent increase in the GPS combination with pembrolizumab. Patients with fewer previous lines of chemotherapy experienced a more favorable median PFS than those with more than two previous lines: for patients with two or fewer previous lines of therapy treated with GPS in combination with pembrolizumab, median PFS was 24 weeks.
    With 43.1 weeks of follow-up the median overall surviva
  • S
    Stephens
    $SLS conversation
    Serious: If the DMC doesn't stop the P3 early for Efficacy and SLS isn't bought by $MRK or $BMY
    What will SLS' market value be when the FDA gets a look at the AML results? When is that?
    Lastly, when will the market begin to appreciate SLS shares in advance of that massively valuable inflection point?
  • B
    Berlin 68
    $XBI conversation
    SLS diverging / up nicely, with shorts covering all what they sold the last couple weeks to hold it down, after great trial data with $MRK $BMY. SLS Is ripe for a squeeze.
  • C
    Cured
    $SLS conversation
    $MRK Gps Keytruda Ovarian Cancer last update "Median overall survival among the patients in this trial is not yet known as all patients are still alive at the time of the analysis, which period of time exceeds nine months.
    Avg Os with existing soc is 9/10 months
    “Based on these early data, it is encouraging to see the induction of WT1-specific T-cell immune responses with the administration of GPS in combination with pembrolizumab with a validated complex ex-vivo immune response assay on peripheral blood from patients with platinum-refractory metastatic ovarian cancer who had undergone numerous prior therapies,” Jeffrey S. Weber, MD, PhD, the deputy director of the Perlmutter Cancer Center at NYU Langone Health, and chair of SELLAS’ Scientific Advisory Board, added in the press release.
  • B
    Berlin 68
    $SLS conversation
    Possible reasons for trading activity
    $ABBV buys SLS, $MRK Buys SLS, $BMY BUYS SLS, IDMC Halts the Phase 3 for Efficacy, FDA AML Approval
  • T
    Thomas
    Merck & Co., Inc.
    Load up people $MRK Getting ready to take off
  • g
    greg
    $SLS conversation
    Though most shorts here are pure liars, I stated, I would not be surprised to see sls jump 4 or 500% in June. The results were what I expected (though the Final, final data is in Oct Nov or Dec for both the $BMY and $MRK Readout), better than all existing therapies for the sickest of patients. Meso 46 vs 22.
    Instead of the price Launching shorts Manipulated the share price down, on some active volume, but nonetheless short sold down. Now they need to cover hence Jerome dman spuds toe walker telomere -
  • R
    Real Immuno Investor 10
    $SLS conversation
    SLS is worth a Billion Now trades for $50M $bmy $mrk In June Gps Keytruda Ovarian Cancer last update "Median overall survival among the patients in this trial is not yet known as all patients are still alive at the time of the analysis, which period of time exceeds nine months.
    Gps Opdivo End stage Meso last update:
    “Median OS was 35.4 weeks, the time at which the data was taken. Stergiou expects the median overall survival to be considerably longer when the next report is delivered
    ..patients with relapsed or refractory mesothelioma have a median OS of 22
  • R
    Real Immuno Investor 10
    $SLS conversation
    PT $40 $50 "...by the End of Q2" SLS has 2 Billion dollar TRIAL hits like what added $.5B to $NKTX
    - Gps Opdivo $BMY Meso patient with a life expectancy of 6-8 weeks, alive 25 months at least
    - 1st Dosed GPS Keytruda $MRK patient w a LE of 9/10 months alive 24 months, so far
    - Moffitt Center GPs P2 AML Secondary remission O Survival 21 months vs 5/6 months in the control patients
    - Sloan Kettering Gps Phase 2 AmL Cr1 patients median OS of 67 months vs 26 with O Az Soc
    - GPS +Pembro 100% patient survival already for as long as the best standard of care average Survival,
    Coming Results in June are 100% guaranteed to better, much better than existing best treatment
    - Dr. Levy Director of Hematologic Research at Baylor Med said its virtually certain Gps P3 will be FDA approved
    - Investigators who see actual GPS P3 patients in clinic Requesting Expanded Access confirms GPS is GOLDEN
    - IDMC now analyzing data for a Possible Halt for Efficacy

    Literally 2,500% ROI is more than likely
  • R
    Real Immuno Investor 10
    $SLS conversation
    PT $40 $50 "...by the End of Q2" SLS has 2 Billion dollar TRIAL hits like what added $.5B to $NKTX
    - Gps Opdivo $BMY Meso patient with a life expectancy of 6-8 weeks, alive 25 months at least
    - 1st Dosed GPS Keytruda $MRK patient w a LE of 9/10 months alive 24 months, so far
    - Moffitt Center GPs P2 AML Secondary remission O Survival 21 months vs 5/6 months in the control patients
    - Sloan Kettering Gps Phase 2 AmL Cr1 patients median OS of 67 months vs 26 with O Az Soc
    - GPS +Pembro 100% patient survival already for as long as the best standard of care average Survival,
    Coming Results in June are 100% guaranteed to better, much better than existing best treatment
    - Dr. Levy Director of Hematologic Research at Baylor Med said its virtually certain Gps P3 will be FDA approved
    - Investigators who see actual GPS P3 patients in clinic Requesting Expanded Access confirms GPS is GOLDEN
    - IDMC now analyzing data for a Possible Halt for Efficacy

    Literally 2,500% ROI is more than likely
  • R
    Real Immuno Investor 10
    $SLS conversation
    PT $40 $50 "...by the End of Q2" SLS has 2 Billion dollar TRIAL hits like what added $.5B to $NKTX
    - Gps Opdivo $BMY Meso patient with a life expectancy of 6-8 weeks, alive 25 months at least
    - 1st Dosed GPS Keytruda $MRK patient w a LE of 9/10 months alive 24 months, so far
    - Moffitt Center GPs P2 AML Secondary remission O Survival 21 months vs 5/6 months in the control patients
    - Sloan Kettering Gps Phase 2 AmL Cr1 patients median OS of 67 months vs 26 with O Az Soc
    - GPS +Pembro 100% patient survival already for as long as the best standard of care average Survival,
    Coming Results in June are 100% guaranteed to better, much better than existing best treatment
    - Dr. Levy Director of Hematologic Research at Baylor Med said its virtually certain Gps P3 will be FDA approved
    - Investigators who see actual GPS P3 patients in clinic Requesting Expanded Access confirms GPS is GOLDEN
    - IDMC now analyzing data for a Possible Halt for Efficacy

    Literally 2,500% ROI is more than likely

    20M shares x $40 $800M Mc for an effective safe therapy that works for end stage, dying mesothelioma and ovarian cancer patients who have exhausted all treatment options.
  • J
    Joe
    $SLS conversation
    Last year, this time SlS traded up to $15 ahead of small adhoc readouts. Now we will see larger, mature results - Gps is worth billions and Big Pharma will be Paying up Bigly. $MRK or $BMY May decide its time to Guppy this baby BIO
    Merck has zero agents for PROC, Keytruda is ineffective as a single agent - they need Gps.
  • C
    Cured
    $SLS conversation
    In a small $nktx P1 trial 2/5 of 2 mrd- patients added $600 M in shareholder value. Patients who had no other treatment options - same as the $bmy Gps mesothelioma P1 combination patients and the $mrk Keytruda P2 Ovarian Cancer patients for that matter.

    — merck and SlS locked the data and are now conducting Joint analysis to be announced in Q2

    Galinpepimut-S (GPS) in combination with pembrolizumab (Keytruda) shows promising antitumor activity and initial immunobiological activity for Wilms Tumor–1 (WT1)–positive ovarian cancer as part of a phase 1/2 clinical trial, according to a press release from SELLAS Life Sciences Group, Inc.1

    Recent data from the study show 100% of patients in this group (n = 11) are still alive and 5 patients (45.5%) are continuing investigational treatment.

    The open-label, multicenter, multi-arm study has a target enrollment goal of 20 patients with relapsed or refractory, platinum-resistant, advanced ovarian cancer. The primary end points are safety and overall response rate, with secondary end points of progression-free survival (PFS) and overall survival (OS).

    Patients in this study who had previously failed second- or third-line therapy comprised 66.7% and 33.3%, respectively. Although OS data are not mature, all patients remained alive at 9 months which compares favorably with historical OS of 9* months with the standard of care.
  • R
    Real Immuno Investor 10
    $SLS conversation
    By the End of Q2 $bmy $Mrk - Gps Nivolumab Meso sarcomotoid patient with a life expectancy of 6-8 weeks, alive 25 months, at least
    - First Dosed GPS Pembro patient w a LE of 9/10 months survived 24 months at least
    - Gps Moffitt Center Phase 2 AML Cr2 patients survived 21 months vs 5/6 months in the the control
    - Gps Memorial Sloan Kettering Phase 2 AmL cr1 patients median os 67 months vs 26 with OAz (New treatment)
    - GPS Pembro 100% patient survival for as long as the best standard of care median average Survival, trial Results announced in June are 100% guaranteed to better much better than existing best treatment.
    - Dr. Levy Director of Hematologic Research at Baylor University Med has said its virtually certain Gps is working as intended.
    - Investigators who see GPS patients in clinic Requesting Expanded Access to Gps

    IDMC is adding all the evidence, are reviewing to Halt for Efficacy
  • R
    Real Immuno Investor 10
    $SLS conversation
    Last year, this time SlS traded up to $15 ahead of small adhoc readouts. Now we will see larger, mature results - Gps is worth billions and Big Pharma will be Paying up Bigly. $MRK or $BMY May decide its time to Guppy this baby BIO
    Merck has zero agents for PROC, Keytruda is ineffective as a single agent - they need Gps.
  • R
    Real Immuno Investor 10
    $SLS conversation
    Next month WE All will wish we Bought more Right now PT $40 $50 "...by the end of Q2"
    SLS has 2 Billion dollar TRIAL hits like what added $.5B to $NKTX
    - Gps Opdivo $BMY Meso patient with a life expectancy of 6-8 weeks, alive 25 months at least
    - 1st Dosed GPS Keytruda $MRK patient w a LE of 9/10 months alive 24 months, so far
    - Moffitt Center GPs P2 AML Secondary remission O Survival 21 months vs 5/6 months in the control patients
    - Sloan Kettering Gps Phase 2 AmL Cr1 patients median OS of 67 months vs 26 with O Az Soc
    - GPS +Pembro 100% patient survival already for as long as the best standard of care average Survival,
    Coming Results in June are 100% guaranteed to better, much better than existing best treatment
    - Dr. Levy Director of Hematologic Research at Baylor Med said its virtually certain Gps P3 will be FDA approved
    - Investigators who see actual GPS P3 patients in clinic Requesting Expanded Access confirms GPS is GOLDEN
    - IDMC now analyzing data for a Possible Halt for Efficacy

    Literally 2,500% ROI is more than likely
  • R
    Real Immuno Investor 10
    $XBI conversation
    $sls 2 binary trial results incoming Q2 - $nktx just added $600B on a 6 patient, end stage p1 in AML
    $BMY Opdivo combination, preliminary response 25% cure rate for end stage, dying Mesothelioma Patients
    $MRK Keytruda combination for end stage ovarian cancer patients, Prelim data had 100% survival for as long as the median survival with standard of care. 100% survival, for as long as the average with standard care means Merck and Sellas are 100% guaranteed to announce survival results better than all other drugs for these dying patients.